Back to Agenda
Tolerability in Immuno-Oncology: Patient Experience as a Core Element of Clinical Trials
Session Chair(s)
Devin Peipert, PHD
Professor of Health Outcomes Measurement
University of Birmingham, United Kingdom
Update on a DIA study advancing patient experience data to assess tolerability in immuno-oncology trials, highlighting conceptual model progress and stakeholder insights for regulatory decisions.
Learning Objective : Describe recent developments from the DIA study integrating patient experience into immuno-oncology tolerability assessments; Examine findings from literature and KOL interviews; Identify strategies for operationalizing a multidimensional tolerability framework; Recognize multistakeholder perspectives to support trial design, data collection, and benefit–risk evaluation.
Speaker(s)
Panelist
Efrat Dotan, MD
Penn Center for Cancer Care Innovation, United States
Executive Medical Director, Ann B Barshinger Cancer Institute, Lancaster General
Panelist
Maria Paula Bautista Acelas, MSC
DIA, United States
Senior Scientific Project Manager
Angela Rylands
Kyowa Kirin International , United Kingdom
Global Head of Patient Centred Outcomes
Panelist
Lia Ridout
-, United States
Patient Advocate
Have an account?